ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough esophageal cancer: targeted combo trial launches
Disease control Not yet recruitingThis phase 3 trial tests whether a new combination of drugs (anlotinib plus benmelstobart) works better than the current standard treatment for advanced esophageal cancer that has certain gene mutations. About 578 adults with this cancer who have not had prior treatment will be r…
Matched conditions: ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated May 17, 2026 06:51 UTC
-
New combo therapy aims to control advanced esophageal cancer
Disease control Not yet recruitingThis study tests a personalized treatment plan for people with advanced esophageal cancer that cannot be removed by surgery. Doctors will use MRI scans to guide chemotherapy and radiation, and also add immunotherapy. The goal is to see if this approach can keep the cancer from gr…
Matched conditions: ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for esophageal cancer: experimental drug YL201 faces chemo in major trial
Disease control Not yet recruitingThis large study tests whether a new medicine called YL201 works better than standard chemotherapy for people with advanced esophageal cancer that has stopped responding to initial treatment. About 440 participants will be randomly assigned to receive either YL201 or a doctor-cho…
Matched conditions: ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC